



Allergen immunotherapy for asthma

รศ. นพ. ต่อพงษ์ ทองงาม

สาขาวิชาโรคภูมิแพ้และอิมมูโนวิทยา

ภาควิชาอายุรศาสตร์

คณะแพทยศาสตร์ศิริราชพยาบาล



Current available treatment

Specific immunotherapy



Allergic rhinitis

- Antihistamine
- Nasal steroid
- Leukotriene modifier

Allergic asthma

- Inhaled steroid
- ICS+LABA
- Leukotriene modifier
- Theophylline-SR
- Anti-IgE



Definition


- The **repeated administration of specific allergens** to patients with **IgE-mediated conditions** for the purpose of providing protection against the allergic symptoms and inflammatory reactions associated with natural exposure to allergens.



Allergen extract




Allergen vaccine





Allergy skin testing







Indication


- Symptoms of **AR and/or asthma** after natural exposure to aeroallergens and demonstrable evidence of **clinically relevant specific IgE.**
- +
- Poor response to allergen avoidance and pharmacotherapy.
 - Unacceptable adverse effects of medications.
 - Wish to reduce or avoid long term pharmacotherapy and the cost of medication.
 - Coexisting allergic rhinitis and asthma



Most Patients with Asthma Have Allergic Rhinitis



Approximately **80%** of asthmatics have allergic rhinitis




Adapted from The Workshop Expert Panel. *Management of Allergic Rhinitis and its Impact on Asthma (ARIA) Pocket Guide. A Pocket Guide for Physicians and Nurses*. 2001; Bousquet J and the ARIA Workshop Group *J Allergy Clin Immunol* 2001;108(5):S147-S334; Sibbald B, Rink E *Thorax* 1991;46:895-901; Leynaert B et al *Am J Respir Crit Care Med* 2000;162:1391-1396.

Allergic Rhinitis Is a Risk Factor for Asthma



- Allergic rhinitis increased the risk of asthma ~3-fold



23-year follow-up of college freshmen undergoing allergy testing; data based on 738 individuals (69% male) with average age of 40 years.

Adapted from Settipane RJ et al *Allergy Proc* 1994;15:21-25.



Effectiveness on allergic rhinitis

- Meta-analysis of prospective, randomized, double-blind, placebo-controlled studies
- All studies of SIT in allergic rhinitis between 1966-1996 were identified.
- **16** studies involving **759** patients with allergic rhinitis.



Effectiveness on allergic rhinitis

- Improve symptoms of allergic rhinitis
(OR 1.81, 95%CI 1.48-2.23).
- Improve symptom-medication score
(P < 0.05).



Effectiveness on asthma

- 75 RCT with a total of 3,188 patients with asthma
- Significant improvement of asthma symptoms, medication use and BHR.
- No consistent effect on lung function.



SIT for asthma: systematic reviews

- 88 RCTs were included.
- 42 SIT for mite, 27 for pollens, 10 for animal dander, and 6 for multiple allergens.
- Only 16 trials were assessed as clearly adequate.



SIT for asthma: systematic reviews

- Significant improvement in asthma symptom score.
- Treat 3 pts. to avoid 1 deterioration in asthma symptom.
- Treat 4 pts. to avoid 1 requiring increased medication.
- Reduce BHR.
- No consistent effect on lung function
- 16 pts with SIT, 1 local reaction.
- 9 pts with SIT, 1 systemic reaction.



Effectiveness of SLIT on asthma

- Meta-analysis including 25 RCT with 1706 patients with asthma.
- SLIT is beneficial for asthma, albeit the magnitude is not large.
- Safer than subcutaneous route.



Effect of SIT added to drug treatment

- A double-blinded RCT in 72 patients with mild to moderate asthma, allergic to HDM.
- ↓ patients requiring rescue β_2 agonist.
- ↑ morning PEF.
- No benefit on the dose of inhaled steroid, asthma symptoms, lung volumes and BHR.




SIT prevents asthma

- 147 subjects with allergic rhinitis, aged 16-25 yr. with grass pollen allergy were followed up for 10 yr after 3-yr course of SIT.
- 3-yr course of SIT have long-term clinical effects.
- Less actively treated subjects had developed asthma (OR 2.5).




SIT prevents asthma



Initial Placebo Trial

Current Trial

Grass pollen allergic rhinitis with 3-5 yr course of SIT.





SIT prevents new sensitization

- 147 children with rhinitis and/or asthma monosensitized to dust mite were recruited.
- 85 underwent SIT, and 62 on medication.
- 25% in SIT, 53% in control developed new sensitization.



Summary

- Specific immunotherapy (SIT) has a role in selected asthma patients.
- SIT prevents new sensitization and asthma in adulthood.
- Effect of SIT lasts for several years after 3-5 yr-course of treatment.



Thank You



Safety



- Systemic reactions
 - conventional schedule: <math><1\%</math>
 - rush immunotherapy
- Systemic reactions usually occur within 30 mins.



Risk factors for systemic reactions

- Uncontrolled diseases
 - uncontrolled asthma
 - cardiovascular diseases
- $FEV_1 < 70\%$ of predicted.
- Taking β -blocker.



Allergen extract/vaccine

- Standardized extract
 - Cat hair or pelt
 - Mite
 - Grass
 - Ragweed
- Non- Standardized extract
 - Dog, other pollens, cockroach, mold



How to do SIT

- Serial dilutions

1:1,000 → 1:100 → 1:10 → Full strength
(maintenance)

- Clear labeling
- Evaluate at 1-yr after starting treatment



How to do SIT

- If not effective, consider:
 - 1) still expose to allergens
 - 2) still expose to non-allergenic trigger
 - 3) type or dose of allergens is not appropriate



Effectiveness on asthma

- Meta-analysis of prospective, randomized, double-blind, placebo-controlled studies
- All studies of SIT in asthmatics between 1966-1998 were identified.
- **24 studies involving 962 asthmatics.**



Effectiveness on asthma

- SIT compared to placebo
 - Improve symptoms of asthma (OR 2.76, 95%CI 2.22-3.42).
 - Improve pulmonary function (OR 2.87, 95%CI 1.82-4.52).
 - Protection against bronchial challenge (OR 2.0, 95%CI 1.46-2.72).




Summary of mechanisms

- A shift from Th2 to Th1
- Immunologic tolerance
- Decrease of specific IgE
- Increase of IgG blocking antibody



Treating Rhinosinusitis Decreased Asthma-Related Resource Utilization

- 61% fewer hospitalizations in treated patients



Retrospective cohort study of costs over a period of up to one year incurred by patients 12 to 60 years of age with both allergic rhinitis and asthma.

Adapted from Crystal-Peters J et al *J Allergy Clin Immunol* 2002;109(1):57-62.